Outcomes assessment in multiple sclerosis clinical trials: a critical analysis

Multiple Sclerosis Journal - Tập 1 Số 1 - Trang 37-47 - 1995
JN Whitaker1, H. McFarland2, Peter Rudge3, Stephen C. Reingold4
1Department of Neurology, University of Alabama and the Birmingham VA Medical Center, Birmingham, Alabama 35294, USA
2Neuroimmunology Branch, NINDS/NIH, Bethesda, Maryland 20892, USA
3Institute of Neurology National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
4Research and Medical Programs Department, National Multiple Sclerosis Society, New York, New York 10017, USA

Tóm tắt

The feasibility and precision of clinical trials for the treatment of MS must be improved Subsequent to the approval by the Food and Drug Administration of the United States of interferon beta-1b as a safe and effective, though not curative, treatment for relapsing-remitting MS, the testing of other agents in this disease has been undertaken or is anticipated. This report summarises the discussions and recommendations of an international workshop held to review critically the elements of current MS therapeutic trials and to identify the most important aspects of clinical evaluation, study design and data analysis that would allow agents for MS to be tested as accurately, rapidly and economically as possible. While acknowledging the many uncertainties about the pathophysiology and natural history of MS, the workshop participants made recommendations about the preferred components to be used in the design of trials which may be different depending on the treatment goal and agent studied. It was concluded that the formulation of a useful clinical trial design must be based on specific guidelines for clinical scales and imaging for which task forces were recommended and subsequently appointed.

Từ khóa


Tài liệu tham khảo

10.1212/WNL.43.4.655

Brown JR, 1979, Neurology, 21, 1

Herndon RM, 1983, Arch Neurol, 40, 663

10.1212/WNL.5.8.580

10.1212/WNL.11.8.686

10.1212/WNL.33.11.1444

10.1212/WNL.40.6.971

10.1212/WNL.34.10.1368

10.1016/S0140-6736(86)91554-0

Potvin AR, 1985, Quantitative Examination of Neurologic Function.

Redekop HK, 1991, Ann Neurol, 30, 255

12 Spilker B. (1991) Guide to Clinical Trials. Raven Press: New York, pp 27–58.

Food and Drug Administration, 1992, Fed Reg, 57, 58941

10.1097/00002371-199210000-00004

10.1007/BF03160168

10.1111/j.1600-0404.1992.tb08047.x

10.1212/WNL.37.11.1754

10.1212/WNL.38.10.1511

10.1002/ana.410250107

10.1093/brain/113.5.1477

10.1002/ana.410290515

10.1002/ana.410340507

10.1093/brain/111.4.927

10.1002/ana.410320609

10.2214/ajr.159.5.1414773

10.1148/radiology.169.1.3420246

10.1002/sim.4780130509

10.1212/WNL.43.4.662

10.1002/ana.410330511

10.1212/WNL.44.4.635

10.1212/WNL.41.8.1251

Grossman RI, 1992, Am J Neuroradiol, 13, 1535

10.1001/archneur.1992.00530260063021

10.1002/jmri.1880020303

10.1148/radiology.182.2.1732968

10.1136/jnnp.54.8.683

10.1126/science.253.5018.390

10.1212/WNL.42.1.63

10.1136/jnnp.55.6.450

Whitaker JN, 1990, Handbook of Multiple Sclerosis, 251

10.1212/WNL.30.11.1155

Whitaker JN, 1982, Clin Immunol Allergy, 2, 469, 10.1016/S0260-4639(22)00052-4

10.1056/NEJM197612232952604

10.1212/WNL.27.10.911

10.1017/S0317167100035757

10.1002/ana.410330104

10.1056/NEJM199108153250704

10.1002/ana.410280514

Noseworthy JH, 1993, Neurology, 43, A355, 10.1212/WNL.43.7.1401

10.1016/0165-5728(91)90101-C

10.1146/annurev.iy.10.040192.001101

52 Matthews WB, et al. (1991) McAlpine's Multiple Sclerosis. Churchill Livingstone: London, pp 321–339.

10.1002/ana.410330602

10.1002/ana.410220516

10.1212/WNL.41.4.540

10.1002/ana.410350511

10.1002/ana.410270603

10.1056/NEJM199312093292403

10.1212/WNL.44.1.166

10.1002/ana.410360106

Thông tin
Thông tin xuất bản

Multiple Sclerosis Journal

Tập 1 Số 1

37-47

Thông tin tác giả